Latest technologies from Texas Portalhttp://texas.technologypublisher.comBe the first to know about the latest inventions and technologies available from Texas Portalen-USSun, 25 Jun 2017 23:54:48 GMTMon, 05 Jun 2017 08:45:06 GMThttp://blogs.law.harvard.edu/tech/rssballinson@utsystem.eduCopyright 2017, Texas PortalImproved Dental Abutment Geometries for Cement-Retained Crownshttp://texas.technologypublisher.com/technology/25433Mon, 05 Jun 2017 08:45:06 GMTbrent.schultze@utdallas.eduhttp://texas.technologypublisher.com/technology/25433Biopsy Site Identification Method and Apparatushttp://texas.technologypublisher.com/technology/25419Thu, 01 Jun 2017 14:59:24 GMTuthsch-otm@uth.tmc.eduhttp://texas.technologypublisher.com/technology/25419Intelligent Textiles Prepared from Nanofiber Yarns and Polymer Fiber Actuatorshttp://texas.technologypublisher.com/technology/25389Tue, 30 May 2017 09:06:49 GMTbrent.schultze@utdallas.eduhttp://texas.technologypublisher.com/technology/25389Encapsulated Thermoacoustic Projector Based on Free-Standing Carbon Nanotube Filmhttp://texas.technologypublisher.com/technology/25385Fri, 26 May 2017 07:52:30 GMTbrent.schultze@utdallas.eduhttp://texas.technologypublisher.com/technology/25385Novel Solution for Selective Adsorption and Release of Gases Within Porous Materialshttp://texas.technologypublisher.com/technology/25384Fri, 26 May 2017 07:37:15 GMTbrent.schultze@utdallas.eduhttp://texas.technologypublisher.com/technology/25384Multistage Nanoparticle Drug Delivery Systemshttp://texas.technologypublisher.com/technology/25364Tue, 23 May 2017 14:45:16 GMTuthsch-otm@uth.tmc.eduhttp://texas.technologypublisher.com/technology/25364Thermochromic Solid-State Organic Semiconductorshttp://texas.technologypublisher.com/technology/25177Thu, 27 Apr 2017 11:08:31 GMTbrent.schultze@utdallas.eduhttp://texas.technologypublisher.com/technology/25177An Environmentally Friendly Solution for Preservation and Increased Nutritional Value of Hay and Foragehttp://texas.technologypublisher.com/technology/25167Mon, 24 Apr 2017 13:41:09 GMTbrent.schultze@utdallas.eduhttp://texas.technologypublisher.com/technology/25167A New Environmentally Friendly Acid for Hydrolysis of Celluloseshttp://texas.technologypublisher.com/technology/25166Mon, 24 Apr 2017 13:41:07 GMTbrent.schultze@utdallas.eduhttp://texas.technologypublisher.com/technology/25166A System for Compliance with Congestive Heart Failure (CHF) Management Guidelineshttp://texas.technologypublisher.com/technology/25165Mon, 24 Apr 2017 13:41:05 GMTbrent.schultze@utdallas.eduhttp://texas.technologypublisher.com/technology/25165Spectrum-Agile Massive MIMO System and Capacity Adaptation Between Uplink and Downlinkhttp://texas.technologypublisher.com/technology/25089Wed, 19 Apr 2017 08:40:10 GMTbrent.schultze@utdallas.eduhttp://texas.technologypublisher.com/technology/25089One pot difunctionalization of hyaluronic acid with thiol and azide groupshttp://texas.technologypublisher.com/technology/25073Fri, 14 Apr 2017 09:50:09 GMTuthsch-otm@uth.tmc.eduhttp://texas.technologypublisher.com/technology/25073ForecastEDhttp://texas.technologypublisher.com/technology/25072Fri, 14 Apr 2017 07:51:23 GMTuthsch-otm@uth.tmc.eduhttp://texas.technologypublisher.com/technology/25072Fabrication of Bone Regeneration Scaffolds and Bone Filler Material Using a Perfusion Flow Systemhttp://texas.technologypublisher.com/technology/25042Fri, 07 Apr 2017 08:28:45 GMTsaenzv@uthscsa.eduhttp://texas.technologypublisher.com/technology/25042Three-Dimensional Scaffold Culture System of Functional Pancreatic Isletshttp://texas.technologypublisher.com/technology/25041Fri, 07 Apr 2017 08:19:47 GMTsaenzv@uthscsa.eduhttp://texas.technologypublisher.com/technology/25041Automated Device for Dynamic Allodynia Testinghttp://texas.technologypublisher.com/technology/24516Thu, 02 Mar 2017 14:47:01 GMTbrent.schultze@utdallas.eduhttp://texas.technologypublisher.com/technology/24516Compatibilized Immiscible Polymer Blends and Molecular Sieve Membraneshttp://texas.technologypublisher.com/technology/24156Tue, 21 Feb 2017 13:34:20 GMTbrent.schultze@utdallas.eduhttp://texas.technologypublisher.com/technology/24156Synthetic Peptide based Delivery System to Target Delivery of Antibacterial Agents (Targeting a Quorum Sensing System)http://texas.technologypublisher.com/technology/24065The emergence of drug-resistant pathogens is a global concern for human health, in the United States at least 2 million people become infected with antibiotic resistant bacteria and it leads to the death of at least 23,000 people per year. Exemplary bacteria are rapidly developing resistance against various antibiotics. Therefore, while continual exploration for novel antibiotics is needed, establishment of alternative antimicrobial strategies based on non-traditional mechanisms is an unmet need in the medical field. Inventors at the University of Texas Health Science Center have developed an ...Tue, 14 Feb 2017 07:40:20 GMTuthsch-otm@uth.tmc.eduhttp://texas.technologypublisher.com/technology/24065Sheath-Core Fibers for Superelastic Electronics, Sensors, and Muscleshttp://texas.technologypublisher.com/technology/23927Fri, 03 Feb 2017 12:42:48 GMTbrent.schultze@utdallas.eduhttp://texas.technologypublisher.com/technology/23927Partially fluorinated proton exchange membranes based on PFCP for fuel cell membraneshttp://texas.technologypublisher.com/technology/23816Technology Description:There is currently a lack of commercially available proton exchange membranes that can withstand the harsh operating conditions of a fuel cell. Commercially available membranes work well under specific temperature and humidity conditions, however their utility is drastically reduced at higher temperatures and lower relative humidity. Researchers at The University of Texas at Dallas have developed membranes that demonstrate the desired properties of a fuel cell membrane: superior conductance and high stability under high temperatures and lower humidity. By blending hydrop...Fri, 13 Jan 2017 14:41:42 GMTbrent.schultze@utdallas.eduhttp://texas.technologypublisher.com/technology/23816High Torque Density Switched Reluctance Motorshttp://texas.technologypublisher.com/technology/23815Fri, 13 Jan 2017 14:41:42 GMTbrent.schultze@utdallas.eduhttp://texas.technologypublisher.com/technology/23815Addition of bioactivity and antibiotics in two-solution bone cementhttp://texas.technologypublisher.com/technology/23814Fri, 13 Jan 2017 14:41:40 GMTbrent.schultze@utdallas.eduhttp://texas.technologypublisher.com/technology/23814Multifunctional Ionic liquids for Surface Modification of Dental Implantshttp://texas.technologypublisher.com/technology/23813Fri, 13 Jan 2017 14:41:40 GMTbrent.schultze@utdallas.eduhttp://texas.technologypublisher.com/technology/23813Unified Lower-Limb Prosthetic Control Strategyhttp://texas.technologypublisher.com/technology/23712Mon, 19 Dec 2016 12:55:45 GMTbrent.schultze@utdallas.eduhttp://texas.technologypublisher.com/technology/23712Monoclonal antibodies against EGFL6 for diagnostic and cancer therapeutic usehttp://texas.technologypublisher.com/technology/22790Tue, 06 Sep 2016 09:20:37 GMTuthsch-otm@uth.tmc.eduhttp://texas.technologypublisher.com/technology/22790Novel Channelrhodopsins for Inhibition of Neuronal Activityhttp://texas.technologypublisher.com/technology/22442Optogenetics is rapidly evolving field that provides the ability to control neurons using light-sensitive proteins called channelrhodopsins (ChRs). When genetically expressed in neurons, ChRs have the ability to selectively manipulate neuronal activity in a light-dependent manner. Gene-therapy using ChRs has the exciting potential to be used to treat patients suffering from disorders caused by aberrant neuronal signaling. Dr. John L. Spudich and his research team have disrupted the field of optogenetics through their discovery and development of first of their kind anion channelrhodopsins (ACR...Wed, 13 Jul 2016 13:16:39 GMTuthsch-otm@uth.tmc.eduhttp://texas.technologypublisher.com/technology/22442Connexin (Cx)43 Hemichannel-Binding Antibodies And Uses Thereofhttp://texas.technologypublisher.com/technology/22285Fri, 17 Jun 2016 14:32:51 GMTuthsch-otm@uth.tmc.eduhttp://texas.technologypublisher.com/technology/22285Nested Nanoparticles for Site-specific, Sequential Drug Deliveryhttp://texas.technologypublisher.com/technology/22070New nested nanoparticles for drug delivery have been developed at UTHealth to deliver multiple drugs in a site-, time-, and sequence-specific manner. These nanoparticles consist of a drug-containing polymeric core made of PLGA, surrounded by an outer shell of cyclodextrin complexed with a second drug. These two delivery components facilitate dual-release kinetics, and have been shown in vivo to be efficacious at inhibiting tumor growth compared to controls. These nanoparticles have been designed for site-specific delivery of cancer therapeutics to tumors but have broad applicability, including...Tue, 24 May 2016 15:00:52 GMTuthsch-otm@uth.tmc.eduhttp://texas.technologypublisher.com/technology/22070Virtual Mitral Valve Repair Simulationhttp://texas.technologypublisher.com/technology/21703Thu, 07 Apr 2016 14:43:50 GMTuthsch-otm@uth.tmc.eduhttp://texas.technologypublisher.com/technology/21703Novel Compounds for the Prevention and Treatment of Clostridium difficile Infectionshttp://texas.technologypublisher.com/technology/21307Thu, 28 Jan 2016 12:20:52 GMTuthsch-otm@uth.tmc.eduhttp://texas.technologypublisher.com/technology/21307Text Understanding in an Ontology Driven Platform, including Data Collection and Processing http://texas.technologypublisher.com/technology/20867 ABSTRACT Systems and method to aid in the collection, representation and mining of data are disclosed. More particularly, embodiments as disclosed may utilize a unifying format to represent data obtained or utilized by a system to facilitate linking between data from different sources and the commensurate ability to mine such data. Specifically, embodiments may represent data as graphs that comprise the concepts and relationships between those concepts. In this manner, concepts in graphs that represent distinct groupings of data may be mapped and knowledge mining with respect to these graphs ...Fri, 13 Nov 2015 12:32:54 GMTuthsch-otm@uth.tmc.eduhttp://texas.technologypublisher.com/technology/20867Fiber Optic Probe for Deep Non-Invasive Raman Spectroscopyhttp://texas.technologypublisher.com/technology/20786Fri, 06 Nov 2015 13:13:47 GMTuthsch-otm@uth.tmc.eduhttp://texas.technologypublisher.com/technology/20786Supplementing culture media with prostaglandin or its analog to enhance the development of embryoshttp://texas.technologypublisher.com/technology/20775Thu, 05 Nov 2015 12:23:11 GMTuthsch-otm@uth.tmc.eduhttp://texas.technologypublisher.com/technology/20775Clinical Language Annotation, Language Modeling and Processing Toolkit (CLAMP)http://texas.technologypublisher.com/technology/20422Tue, 29 Sep 2015 11:33:57 GMTuthsch-otm@uth.tmc.eduhttp://texas.technologypublisher.com/technology/20422Stroke: Conversations and Explanationshttp://texas.technologypublisher.com/technology/20147Mon, 24 Aug 2015 09:40:43 GMTuthsch-otm@uth.tmc.eduhttp://texas.technologypublisher.com/technology/20147Agglomerated particles responding to hypoglycemiahttp://texas.technologypublisher.com/technology/20083Wed, 05 Aug 2015 11:23:41 GMTuthsch-otm@uth.tmc.eduhttp://texas.technologypublisher.com/technology/20083Methods to Produce Novel Analgesic Drugshttp://texas.technologypublisher.com/technology/19164Mon, 04 May 2015 12:23:27 GMTsaenzv@uthscsa.eduhttp://texas.technologypublisher.com/technology/19164Novel Micro RNA as a Tumor Suppressorhttp://texas.technologypublisher.com/technology/18962Thu, 23 Apr 2015 14:29:19 GMTsaenzv@uthscsa.eduhttp://texas.technologypublisher.com/technology/18962Novel hamstring stretching device to treat lower back painhttp://texas.technologypublisher.com/technology/18961Thu, 23 Apr 2015 13:48:30 GMTsaenzv@uthscsa.eduhttp://texas.technologypublisher.com/technology/18961Potential Cancer Therapeutic: TGF-beta Traphttp://texas.technologypublisher.com/technology/18925Tue, 21 Apr 2015 11:13:06 GMTsaenzv@uthscsa.eduhttp://texas.technologypublisher.com/technology/18925Non-Hydrolysable ATP for Treatment of Primary and Metastatic Cancerhttp://texas.technologypublisher.com/technology/18885Thu, 16 Apr 2015 12:02:50 GMTsaenzv@uthscsa.eduhttp://texas.technologypublisher.com/technology/18885Time Sensitive Foley Catheter Alarmhttp://texas.technologypublisher.com/technology/18884Thu, 16 Apr 2015 11:53:55 GMTsaenzv@uthscsa.eduhttp://texas.technologypublisher.com/technology/18884Use of Capsazepine and Analogs for Treatment of Cancerhttp://texas.technologypublisher.com/technology/18877Thu, 16 Apr 2015 08:40:56 GMTsaenzv@uthscsa.eduhttp://texas.technologypublisher.com/technology/18877In Vivo Methods to Induce Pancreatic Beta Cell Formation for Treatment of Diabeteshttp://texas.technologypublisher.com/technology/18857Mon, 13 Apr 2015 10:37:28 GMTsaenzv@uthscsa.eduhttp://texas.technologypublisher.com/technology/18857miRNAs as novel therapeutic adjuvants and biomarkers for the prognosis and treatment of drug resistant breast cancershttp://texas.technologypublisher.com/technology/18856Fri, 10 Apr 2015 14:22:45 GMTsaenzv@uthscsa.eduhttp://texas.technologypublisher.com/technology/18856Allosteric Proteasome Inhibitors for Treatment of Cancerhttp://texas.technologypublisher.com/technology/18848Fri, 10 Apr 2015 10:08:55 GMTsaenzv@uthscsa.eduhttp://texas.technologypublisher.com/technology/18848Method and Platform for Selectively Labeling RNAhttp://texas.technologypublisher.com/technology/18847The invention pertains to a three step initiation, elongation and termination method and platform for synthesizing selectively labeled RNA molecules by first polymerizing a first liquid phase RNA molecule from a solid phased DNA template fixed onto a solid phase. The method includes the steps of incubating the solid and liquid phases at appropriate elongation temperatures and then terminating elongation by a separation stage where the phases are incubated at near 0 degrees Celsius where it selectively terminates RNA elongation. The steps can be repeated by the number bases (rNTPs) in the fina...Fri, 10 Apr 2015 08:58:34 GMTsaenzv@uthscsa.eduhttp://texas.technologypublisher.com/technology/18847Broadly Protective Pneumococcal Vaccine with Cardiac Protectionhttp://texas.technologypublisher.com/technology/18846With the emergence of pneumococcal infections caused by non-vaccine serotypes and multidrug resistant strains, this broadly effective vaccine may be the best strategy for decreasing morbidity and mortality. Because it also protects against adverse cardiac events during and after pneumococcal pneumonia, it has strong potential as a vaccine for seniors who already have cardiovascular disease and it provides an additional indication for a pneumococcal vaccine outside of the current vaccine recommendations. Phase 1 clinical study is ongoing. This novel indication is part of a portfolio cr...Fri, 10 Apr 2015 08:49:24 GMTsaenzv@uthscsa.eduhttp://texas.technologypublisher.com/technology/18846A Thin-Film Capacitive Sensor with Multiple Applicationshttp://texas.technologypublisher.com/technology/18845Fri, 10 Apr 2015 08:43:48 GMTsaenzv@uthscsa.eduhttp://texas.technologypublisher.com/technology/18845Methods and Composition for Inhibiting Proto-Oncogene PELP1http://texas.technologypublisher.com/technology/18844Fri, 10 Apr 2015 07:31:08 GMTsaenzv@uthscsa.eduhttp://texas.technologypublisher.com/technology/18844Phospholipid Associated 5-ASA for the Treatment of Inflammatory Bowel Diseasehttp://texas.technologypublisher.com/technology/15875 Inflammatory Bowel Disease (IBD) which represents a spectrum of diseases of the lower GI tract, notably Ulcerative Colitis (UC) and Crohn’s Disease (CD), is one of the most common gastrointestinal (GI) afflictions in the United States and Europe. It is also noteworthy that the incidence of UC has increased 2-3 fold in China and other counties in Asia adopting a more Westernized diet/lifestyle over the past decade. It has been estimated by the CDC that health care cost of $1.7 billion in the US are directly attributable to patients afflicted with UC and CD. When one includes los...Mon, 15 Sep 2014 11:14:44 GMTuthsch-otm@uth.tmc.eduhttp://texas.technologypublisher.com/technology/15875Low-Cost, Small-Size Multi-String LED Driver Circuit Architecturehttp://texas.technologypublisher.com/technology/15683Wed, 06 Aug 2014 14:03:33 GMTbrent.schultze@utdallas.eduhttp://texas.technologypublisher.com/technology/15683Enterotoxigenic Escherichia coli Isolates Identified from Patients with Travelers' Diarrheahttp://texas.technologypublisher.com/technology/15419Tue, 24 Jun 2014 13:08:22 GMTuthsch-otm@uth.tmc.eduhttp://texas.technologypublisher.com/technology/15419Antibiotic Microspheres For Treatment Of Infections And Osteomyelitishttp://texas.technologypublisher.com/technology/14790Thu, 20 Mar 2014 08:54:25 GMTuthsch-otm@uth.tmc.eduhttp://texas.technologypublisher.com/technology/14790Compression and stabilization for foot and ankle surgery in diabetic patientshttp://texas.technologypublisher.com/technology/14222Tue, 14 Jan 2014 07:44:27 GMTsaenzv@uthscsa.eduhttp://texas.technologypublisher.com/technology/14222Protective matrix for intracorporeal biosensors that improves gastrointestinal leak detection, detects air leaks after lung surgery, and measures cardiac output after heart surgeryhttp://texas.technologypublisher.com/technology/14096Wed, 18 Dec 2013 08:19:53 GMTsaenzv@uthscsa.eduhttp://texas.technologypublisher.com/technology/14096Advanced Cervical Ripening System (ACRS)http://texas.technologypublisher.com/technology/14092Tue, 17 Dec 2013 13:40:49 GMTsaenzv@uthscsa.eduhttp://texas.technologypublisher.com/technology/14092Method and Apparatus for Transferring an Array of Oriented Carbon Nanotubeshttp://texas.technologypublisher.com/technology/12721Fri, 07 Jun 2013 13:59:21 GMTbrent.schultze@utdallas.eduhttp://texas.technologypublisher.com/technology/12721A Novel Quantitative Low-Light Imaging Modality That Enables Near-Best Parameter Estimation Accuracieshttp://texas.technologypublisher.com/technology/12427Wed, 01 May 2013 12:49:18 GMTbrent.schultze@utdallas.eduhttp://texas.technologypublisher.com/technology/12427Cytotoxic compounds from invasive salvinias (Salvinia spp.) against human tumor cellshttp://texas.technologypublisher.com/technology/12373Tue, 23 Apr 2013 10:12:37 GMTsaenzv@uthscsa.eduhttp://texas.technologypublisher.com/technology/12373Alternatively transcribed and mutated forms of NOXA1 protein and its homologues as selective inhibitors of NADPH oxidases of the NOX familyhttp://texas.technologypublisher.com/technology/12292Thu, 11 Apr 2013 09:59:49 GMTsaenzv@uthscsa.eduhttp://texas.technologypublisher.com/technology/12292An anatomically-referenced fiducial marker for registration of CT data for digital subtractionhttp://texas.technologypublisher.com/technology/12291Thu, 11 Apr 2013 09:59:47 GMTsaenzv@uthscsa.eduhttp://texas.technologypublisher.com/technology/12291Novel Compounds and Methods of Use for the Treatment and Prevention of Cancer via Inhibition of the K-Ras Pathwayhttp://texas.technologypublisher.com/technology/12262Tue, 02 Apr 2013 13:33:12 GMTuthsch-otm@uth.tmc.eduhttp://texas.technologypublisher.com/technology/12262Method and Apparatus for Stent Deployment with Enhanced Delivery of Bio-Active Agentshttp://texas.technologypublisher.com/technology/11978 A stent for use in animals including humans is disclosed which includes unprotected and protected regions, each protected regions including a bioactive or biopenetrating agent containing therein where the protected regions are protected by the unprotected regions when the stent is in its undeployed state which has a smaller cross-sectional dimension than the stent in its deployed state. And when the stent is in its deployed state the bioactive or biopenetrating agent(s) are brought into direct and intimate contact with a tissue or interior of a blood vessel of an animal including ...Mon, 04 Mar 2013 09:50:16 GMTsaenzv@uthscsa.eduhttp://texas.technologypublisher.com/technology/11978Novel Class of pH Responsive and Renal Clearable Tumor Imaging Agentshttp://texas.technologypublisher.com/technology/11946Tue, 26 Feb 2013 14:36:00 GMTbrent.schultze@utdallas.eduhttp://texas.technologypublisher.com/technology/11946Novel Nitric Oxide Releasing Surgical Sutures, Bandages and Fabricshttp://texas.technologypublisher.com/technology/11945Non-Confidential DescriptionThe technology is novel nitric oxide (NO) releasing acrylonitrile-based copolymer and terpolymer fibers that can be used as surgical sutures or non-woven bandages and fabrics that enhance wound healing. These copolymers have a higher NO loading capacity per gram than other known NO releasing acrylonitrile polymers. In addition, the fibers are coated with biodegradable polymers that allow for the timed, slow release of NO when the suture, bandage or fabric is in contact with the wound. These fibers have a long shelf life and when used in wound closure applications ha...Tue, 26 Feb 2013 13:57:55 GMTbrent.schultze@utdallas.eduhttp://texas.technologypublisher.com/technology/11945Low-Cost, Small-Size Multi-String LED Driver Circuit Architecturehttp://texas.technologypublisher.com/technology/11934Mon, 25 Feb 2013 14:01:34 GMTbrent.schultze@utdallas.eduhttp://texas.technologypublisher.com/technology/11934Real-Time Automatic Tuning of Noise Suppression for Cochlear Implants and Hearing Aidshttp://texas.technologypublisher.com/technology/11933Mon, 25 Feb 2013 13:11:27 GMTbrent.schultze@utdallas.eduhttp://texas.technologypublisher.com/technology/11933A method to better predict the likelihood that endocrine therapy alone after surgical intervention will be sufficient to treat patients with estrogen-receptor-positive breast cancerhttp://texas.technologypublisher.com/technology/11848Thu, 07 Feb 2013 13:30:05 GMTsaenzv@uthscsa.eduhttp://texas.technologypublisher.com/technology/11848Compositions and Methods for Regulation of Stem Cell Survival, Proliferation, and Differentiationhttp://texas.technologypublisher.com/technology/11691Wed, 09 Jan 2013 11:10:45 GMTuthsch-otm@uth.tmc.eduhttp://texas.technologypublisher.com/technology/11691"Pedinap" - A Pediatric Anesthesia/Pharmacological Agent Induction Devicehttp://texas.technologypublisher.com/technology/11596Mon, 10 Dec 2012 15:41:06 GMTuthsch-otm@uth.tmc.eduhttp://texas.technologypublisher.com/technology/11596USB Port Security And Access Control Softwarehttp://texas.technologypublisher.com/technology/11582Wed, 05 Dec 2012 07:10:22 GMTuthsch-otm@uth.tmc.eduhttp://texas.technologypublisher.com/technology/11582A High-Efficiency System for in vitro and in vivo Biotinylationhttp://texas.technologypublisher.com/technology/11174Wed, 26 Sep 2012 12:53:58 GMTsaenzv@uthscsa.eduhttp://texas.technologypublisher.com/technology/11174Automatically Bridging the Semantic Gap in Virtual Machine Introspectionhttp://texas.technologypublisher.com/technology/10045Wed, 15 Aug 2012 12:06:21 GMTbrent.schultze@utdallas.eduhttp://texas.technologypublisher.com/technology/10045Standards-Compatible Method for Near-Best Signal Throughput in Mobile Wireless Communicationshttp://texas.technologypublisher.com/technology/10044Wed, 15 Aug 2012 11:30:22 GMTbrent.schultze@utdallas.eduhttp://texas.technologypublisher.com/technology/10044Preparation and Use of Alveoar Cells to Treat Lung Disordershttp://texas.technologypublisher.com/technology/9854Mon, 23 Jul 2012 14:58:53 GMTuthsch-otm@uth.tmc.eduhttp://texas.technologypublisher.com/technology/9854New Red Shifted Channelrhodopsins with Rapid Kineticshttp://texas.technologypublisher.com/technology/9557Fri, 15 Jun 2012 15:33:46 GMTuthsch-otm@uth.tmc.eduhttp://texas.technologypublisher.com/technology/9557Novel Method for Greatly Increasing Liposomal Drug Delivery to Lymph Nodeshttp://texas.technologypublisher.com/technology/9290Wed, 30 May 2012 09:00:30 GMTsaenzv@uthscsa.eduhttp://texas.technologypublisher.com/technology/9290Mediastinal Needle Biopsyhttp://texas.technologypublisher.com/technology/9289Wed, 30 May 2012 09:00:28 GMTsaenzv@uthscsa.eduhttp://texas.technologypublisher.com/technology/9289Biscrolling Nanopowders and Carbon nanotube Sheets into Fibers, Yarns and Textileshttp://texas.technologypublisher.com/technology/9122Non-Confidential Description:The technology is the first known method to spin biscrolled fibers/yarns from nanopowder materials using carbon nanotube (CNT) sheets as the host. Nanopowder materials (nanoparticles, nanofibers) are loaded onto the CNT sheets to form bi-layered sheets, which are then scrolled into fibers. A key advantage of this technology is that it enables the functional nanopowder to be the largest component of the yarns constituting 95-99% (by weight) of the yarn, thereby ensuring that the properties exhibited by the yarn are largely those of the nanopowder. Nanopowders with d...Wed, 14 Mar 2012 14:05:20 GMTbrent.schultze@utdallas.eduhttp://texas.technologypublisher.com/technology/9122Anti-STAM Monoclonal Antibodieshttp://texas.technologypublisher.com/technology/8650Thu, 05 Jan 2012 12:30:18 GMTuthsch-otm@uth.tmc.eduhttp://texas.technologypublisher.com/technology/8650Treatment and Prevention of Vascular Disease with Hybrid Cyclooxygenase:Eicosanoid Proteinshttp://texas.technologypublisher.com/technology/8258 Market: Some form of vascular disease effects one in four Americans, and costs for treatment reach into the billions. Prostanoids are an important, and emerging, therapeutic target in the campaign against vascular disease. Competitors and Current Problems: The prostanoid synthesis pathway is complicated, difficult to direct, and can have multiple end results, not all of them favorable. For example, some of the recent issues in the media and scientific community surrounding COX-2 inhibitors (such as increased potential of heart attacks among patients on COX-2 inhibitors) may involve u...Tue, 29 Nov 2011 09:53:17 GMTuthsch-otm@uth.tmc.eduhttp://texas.technologypublisher.com/technology/8258Targeting Tumors by Pattern Recognition: A Paradigm shift in Targeted Therapeuticshttp://texas.technologypublisher.com/technology/8257 Market: The American Cancer Society estimates that more than 500,000 people will die from cancer in the U.S. in 2007. Many cancer deaths, specifically from cancers of the colon, breast, rectum, and uterine cervix cancers, could be significantly reduced with earlier detection and improved therapy. Cancer treatment of the 15 most common cancers accounted for an estimated $72.1 billion of medical expenditures in the US in 2004. World wide, IMS Health reported that drug companies exceeded $34 billion in sales of cancer drugs in 2006. Competitors and Current Problems: The holy grail of can...Tue, 29 Nov 2011 09:53:16 GMTuthsch-otm@uth.tmc.eduhttp://texas.technologypublisher.com/technology/8257SUMO-Specific Protease Nucleotides and Proteins for Diagnosing Hyperpoliferative Diseaseshttp://texas.technologypublisher.com/technology/8256Market: Prostate cancer is the second most common cancer, and second leading cause of cancer death, in American men. The American Cancer Society predicts over 186,000 new diagnoses of prostate cancer, and over 28,000 deaths in the US in 2008. With early detection being key to a better prognosis, a significant number of people are demanding faster and more accurate diagnosis, and more targeted, efficient, and effective therapies. Competitors and Current Problems: One diagnostic of prostate cancer is by the PSA blood tests. Unfortunately, if higher than normal levels of PSA are detected ...Tue, 29 Nov 2011 09:53:16 GMTuthsch-otm@uth.tmc.eduhttp://texas.technologypublisher.com/technology/8256Structure of Proline- and Arginine-Rich Peptides that Lead to Inhibition of Inflammation and Induction of Angiogenesishttp://texas.technologypublisher.com/technology/8255The Technology: PR39, a naturally produced proline-and-arginine-rich peptide consisting of 39 amino acids, induces angiogenesis and reduces inflammation in mouse models. Through structural and biochemical investigations of PR11, a truncated form of PR39, researchers at the University of Texas Health Science Center at Houston (UTHSC-H) have identified that the 20S proteasome-inhibiting activity of PR39 depends on specific amino acids and structural characteristics. They have also discovered a novel 12-amino acid peptide that has comparable activity as PR39. The linear amino acid sequenc...Tue, 29 Nov 2011 09:53:15 GMTuthsch-otm@uth.tmc.eduhttp://texas.technologypublisher.com/technology/8255Resuscitation From Shockhttp://texas.technologypublisher.com/technology/8251 Market: The Clinical Decision Support System (CDSS) market in Europe alone is estimated to grow to near $430.7 billion by 2012. The American Hospital Association (AHA) reported in a 2006 survey that the number of hospitals adopting moderate to high use of IT systems in general increased 37% from 2005. With more than $37 million patient admissions in 2006 to AHA registered hospitals, the market for increased IT adoption, including CDSS, has very lucrative potential. Competitors and Current Problems: Shock resuscitation after severe injury and blood loss is an emergent effort to regain normal h...Tue, 29 Nov 2011 09:53:13 GMTuthsch-otm@uth.tmc.eduhttp://texas.technologypublisher.com/technology/8251Mesodermal-Like Cells for Treatment Of Ischemiahttp://texas.technologypublisher.com/technology/8248Market: Peripheral artery disease affects 8-12 million Americans. Patients experience pain, numbness, and ulcers. Mobility can be affected, and gangrene can set in. It is estimated that there are 150,000 amputations each year in the United States is due to critical leg ischemia. Of those, the peri-operative mortality rate for below the knee amputations is 5-10%, with a 15-20% peri-operative mortality rate for above the knee amputations. In addition, it is estimated that 30% of first time amputees will require a second amputation. Further, patients with critical limb ischemia have an el...Tue, 29 Nov 2011 09:53:11 GMTuthsch-otm@uth.tmc.eduhttp://texas.technologypublisher.com/technology/8248Bone Graft Scaffolds with High-Strength and High-Porosityhttp://texas.technologypublisher.com/technology/8247Tue, 29 Nov 2011 09:53:11 GMTuthsch-otm@uth.tmc.eduhttp://texas.technologypublisher.com/technology/8247HRS/HRS-2 Polyclonal Antibodyhttp://texas.technologypublisher.com/technology/8125 Polyclonal Antibodies Against HRS The Technology: Dr. Andrew Bean at the University of Texas Health Science Center at Houston (UTHealth) has developed a polyclonal antibody to Hrs. Hrs is a protein that plays a role in the growth factor signaling pathways. Cellular expression of hrs-2 can be determined via the polyclonal Hrs antibody. This antibody will be useful in determining the relationship between growth factor receptor tyrosine kinases and tyrosine phosphorylation of Hrs. Publications:• Growth factor-induced tyrosine phosphorylation of Hrs, a novel 115-kilodalton protein with a...Thu, 03 Nov 2011 09:50:43 GMTuthsch-otm@uth.tmc.eduhttp://texas.technologypublisher.com/technology/8125Inhibitors of Cyclic Nucleotide Synthesis and Their Usehttp://texas.technologypublisher.com/technology/8124 Market: The over production of cyclic nucleotides such as cGMP and cAMP are critical factors in many diseases. The most common causes of diarrhea in humans and animals are mediated by elevated cGMP and are induced by toxins of pathogenic bacteria. The need for novel therapies for both the human and veterinary medical fields is tremendous. Diarrheal diseases are among the worlds leading causes of death, especially in children. The pathology resulting from edema factor of B. anthracis is mediated by cAMP and while antibiotics kill the organism itself, it is often the accumulated edema fa...Thu, 03 Nov 2011 09:50:00 GMTuthsch-otm@uth.tmc.eduhttp://texas.technologypublisher.com/technology/8124Novel Bisphosphonate Formulation with Therapeutic Use in Osteoporosishttp://texas.technologypublisher.com/technology/8123 Market: There is a large market demand for therapeutic compounds addressing bone disease. Osteoporosis, osteitis deformans, or Paget?s disease, bone metastasis, multiple myeloma, and others result in bone fragility. It is noted that metastases to the bone occur in up to 75% of breast and prostate cancers. Of the above listed bone diseases, osteoporosis is a major indication with thirty-five million people in the seven major pharmaceutical markets (U.S., France, Germany, Italy, Spain, UK, and Japan) afflicted by osteoporosis. With this type of demand, it is not surprising that a recent analysi...Thu, 03 Nov 2011 09:49:12 GMTuthsch-otm@uth.tmc.eduhttp://texas.technologypublisher.com/technology/8123Immuno-Diagnosis of Lyme Diseasehttp://texas.technologypublisher.com/technology/8119Thu, 03 Nov 2011 09:42:16 GMTuthsch-otm@uth.tmc.eduhttp://texas.technologypublisher.com/technology/8119A Method for Generating Poroelastograms in Vivohttp://texas.technologypublisher.com/technology/8078Mon, 24 Oct 2011 09:15:59 GMTuthsch-otm@uth.tmc.eduhttp://texas.technologypublisher.com/technology/8078Application of constitutively active soluble guanylyl cyclase (sGC) in prevention of cGMP-dependent pathophysiology and drug developmenthttp://texas.technologypublisher.com/technology/8071 Treatment Or Prevention Of Cgmp-Dependent Pathophysiology With A Mutant Variant Of A Soluble Guanylyl Cyclase Market: The technology has the potential to reach a multitude of markets, such as: cardiovascular disease, treatment and prevention of tumors, treatment of penile dysfunction, and treatment of septic shock. Competitors and Current Problems: It is known that soluble guanylyl cyclase (sGC) is an important enzyme that is involved in the regulation of cardiovascular homeostasis and pathologies (blood pressure, atherosclerosis, and septic shock), neurotransmission and sensory percep...Wed, 19 Oct 2011 08:27:05 GMTuthsch-otm@uth.tmc.eduhttp://texas.technologypublisher.com/technology/8071Paclitaxel Resistant and Dependent Cell Lineshttp://texas.technologypublisher.com/technology/8070 The Technology: Dr. Fernando Cabral at the University of Texas Health Science Center at Houston (UTHealth) has developed a series of mutant cell lines with altered sensitivity to antimitotic drugs. Paclitaxel is a drug that binds to polymerized tubulin and inhibits microtubule disassembly. One of the major limitations in using these drugs, however, is the emergence of drug resistant tumor cells. The inventor has found that some tubulin isotypes alter sensitivity to antimitotic drugs by perturbing microtubule assembly, while others have little effect on assembly but increase the binding...Wed, 19 Oct 2011 08:27:05 GMTuthsch-otm@uth.tmc.eduhttp://texas.technologypublisher.com/technology/8070<![CDATA[OV-1 & OV-6 Hybridoma]]>http://texas.technologypublisher.com/technology/8068Wed, 19 Oct 2011 08:27:04 GMTuthsch-otm@uth.tmc.eduhttp://texas.technologypublisher.com/technology/8068Mouse Embryonic Stem Cell Line EZ-BL6http://texas.technologypublisher.com/technology/8067 Mouse Embryonic Stem Cell Line EZ-BL6 The Technology: Researchers at the University of Texas Health Science Center at Houston (UTHealth) have developed complement anaphylatoxin C5a-deficient mice via the disruption of the C5aR gene. It is becoming increasingly clear that C5aR plays an important role in the regulation of many physiological and cellular responses characteristic of acute shock and that the C3aR functions to temper the immune response in acute shock. This well-characterized model lacks the complement C5a, making it an excellent model for studying the relationship between C...Wed, 19 Oct 2011 08:27:04 GMTuthsch-otm@uth.tmc.eduhttp://texas.technologypublisher.com/technology/8067HRS/HRS-2 Monoclonal Antibodyhttp://texas.technologypublisher.com/technology/8066 Monoclonal Antibodies Against HRS-2 The Technology: Dr. Andrew Bean at the University of Texas Health Science Center at Houston (UTHealth) has developed a monoclonal antibody to Hrs-2. Hrs-2 is a protein that plays a role in the formation and dissolution of protein complexes during vesicular formation. Cellular expression of hrs-2 can be determined via the monoclonal hrs-2 antibody. This antibody will be useful in determining how hrs-2 is regulated and tracking hrs-2 interaction during vesicular trafficking. Publications:• The cellular and developmental expression of hrs-2 in rat. Eur...Wed, 19 Oct 2011 08:27:03 GMTuthsch-otm@uth.tmc.eduhttp://texas.technologypublisher.com/technology/8066E. coli strain AD93/pTMG3 (lacking phosphatidylethanolamine (PE) and contain a-monoglucosyldiacylglycerol MGlcDAG))http://texas.technologypublisher.com/technology/8065 Modified E. coli Strain AD93/pTMG3 The Technology: Dr. William Dowhan at the University of Texas Health Science Center at Houston (UTHealth) has developed a bacterial strain to construct null mutants in specific steps of phospholipid biosynthesis. The anionic phospholipid (phosphatidylglycerol and cardiolipin) content of the mitochondria can be varied and controlled in these mutants. This bacterial strain lacks phosphatidylethanolamine (PE) and contains monoglucosyldiacylglycerol. At present, the role of individual phospholipids in specific membrane functions is not completely underst...Wed, 19 Oct 2011 08:27:03 GMTuthsch-otm@uth.tmc.eduhttp://texas.technologypublisher.com/technology/8065Factor B KO Mouse on C57/BL/6 Genetic Backgroundhttp://texas.technologypublisher.com/technology/8064 Factor B KO Mouse on C57/Bl/6 Genetic Background The Technology: Researchers at the University of Texas Health Science Center at Houston (UTHealth) have developed complement factor B-deficient mice on C57Black6 background via the disruption of the murine Bf, exon 3 through exon 7. It is becoming increasingly clear that factor B plays an important role in the regulation of the alternative complement pathway. The role of factor B in disease pathogenesis, however, is unclear. This well-characterized model lacks the complement factor B, making it an excellent model for studying the role of...Wed, 19 Oct 2011 08:27:02 GMTuthsch-otm@uth.tmc.eduhttp://texas.technologypublisher.com/technology/8064E. coli strain JA200 carrying plasmid pPS3155-lambda (JA200/pPS3155-A)http://texas.technologypublisher.com/technology/8063 E. coli Strain JA200 Carrying Plasmid pPS3155-lambda The Technology: Dr. William Dowhan at the University of Texas Health Science Center at Houston (UTHealth) has developed a bacterial strain to construct null mutants in specific steps of phospholipid biosynthesis. The anionic phospholipid (phosphatidylglycerol and cardiolipin) content of the mitochondria can be varied and controlled in these mutants. This bacterial strain lacks phosphatidylethanolamine (PE) and contains monoglucosyldiacylglycerol. At present, the role of individual phospholipids in specific membrane functions is not c...Wed, 19 Oct 2011 08:27:02 GMTuthsch-otm@uth.tmc.eduhttp://texas.technologypublisher.com/technology/8063Cells with variable beta-tubulin compositionhttp://texas.technologypublisher.com/technology/8062Wed, 19 Oct 2011 08:27:01 GMTuthsch-otm@uth.tmc.eduhttp://texas.technologypublisher.com/technology/8062C5a Receptor "Knock out" Micehttp://texas.technologypublisher.com/technology/8061 C5a Receptor "Knock out" Mice The Technology: A researcher at the University of Texas Health Science Center at Houston (UTHealth) has developed complement anaphylatoxin C5a receptor-deficient mice on C57Black6 genetic background via the disruption of the C5aR gene. It is becoming increasingly clear that C5aR plays an important role in the regulation of many physiological and cellular responses characteristic of acute shock and that the C3aR functions to temper the immune response in acute shock. This well-characterized model lacks the complement C5a, making it an excellent model for st...Wed, 19 Oct 2011 08:27:01 GMTuthsch-otm@uth.tmc.eduhttp://texas.technologypublisher.com/technology/8061C3a Receptor "Knock out" Micehttp://texas.technologypublisher.com/technology/8060 C3a Receptor "Knock Out" Mice Market: Global sales of asthma and COPD treatments are currently worth around US$20 billion. In the US asthma affected 29.5 million people in 2005. Asthmatics visited the doctor in offices and outpatient clinics 14.6 million times in 2004, and there were 1.8 million visits to the emergency room. Unfortunately, asthma was the cause of death for 3,780 people in the US in 2004. There is a significant and growing market looking for earlier diagnosis and better treatment options. The Technology: A researcher at the University of Texas Health Science Center at H...Wed, 19 Oct 2011 08:27:00 GMTuthsch-otm@uth.tmc.eduhttp://texas.technologypublisher.com/technology/8060Bacterial Strain (AD93/pDD72) with Altered Phospholipid Composition for the Production Cardiolipinhttp://texas.technologypublisher.com/technology/8059 Bacterial Strain with Altered Phospholipid Composition for the Production of Cardiolipin The Technology: Dr. William Dowhan at the University of Texas Health Science Center at Houston (UTHSC-H) has developed a bacterial strain to construct null mutants in specific steps of phospholipid biosynthesis. The anionic phospholipid (phosphatidylglycerol and cardiolipin) content of the mitochondria can be varied and controlled in these mutants. Cardiolipin is an essential lipid of the mitochondria and until recently has been understudied as to function and regulation of synthesis because of the...Wed, 19 Oct 2011 08:27:00 GMTuthsch-otm@uth.tmc.eduhttp://texas.technologypublisher.com/technology/8059Antipeptide antibodies which recognize specific somastatin receptor subtypeshttp://texas.technologypublisher.com/technology/8058 Antipeptide Antibodies That Recognize Specific Somatostatin Receptor Subtypes The Technology: This patent covers: 1. A method for developing somatostatin receptor subtype specific antibodies. 2. Antibodies developed using this method to identify somatostatin receptor subtypes belonging to the seven transmembrane domain receptor family. 3. The use of these antibodies, alone or in kit form, to identify somatostatin receptors in tissues or protein extracts. The utility of the patented technology is founded upon its ability to selectively identify somatostatin receptor subtypes and thus w...Wed, 19 Oct 2011 08:26:59 GMTuthsch-otm@uth.tmc.eduhttp://texas.technologypublisher.com/technology/8058Anti Sentrin Antibodyhttp://texas.technologypublisher.com/technology/8057 Anti-Sentrin (Sumo-1) Polyclonal Antibody Background: Small Ubiquitin-like Modifier (SUMO) is a family of proteins that modify other proteins by attaching and detaching covalently. SUMO modification of proteins has many functions, including protein stability, nuclear-cytosolic transport, and transcriptional regulation. Such fundamental activities lead to potential market impact in a wide array of fields such as oncology, immunology, and metabolics. The Technology : Dr. Edward Yeh at the University of Texas Health Science Center at Houston (UTHealth) has developed an anti-Sentrin polycl...Wed, 19 Oct 2011 08:26:59 GMTuthsch-otm@uth.tmc.eduhttp://texas.technologypublisher.com/technology/8057Anti-OPN Polyclonal Antiserahttp://texas.technologypublisher.com/technology/8056 Anti-OPN Polyclonal Antisera The Technology: Researchers at the University of Texas Health Science Center at Houston (UTHSC-H) have developed methods and compositions to analyze and study sialic rich proteins found in osteopontin (OPN), a type of mineralized tissue containing non-collagenous proteins. More specifically, Western immunoblots were performed with anti-OPN polyclonal antisera raised from rabbits. OPN has never been detected in dentin extracts by Western immunoblotting until now, making the antisera an excellent tool for further research into the formation of bone and denti...Wed, 19 Oct 2011 08:26:58 GMTuthsch-otm@uth.tmc.eduhttp://texas.technologypublisher.com/technology/8056Anti NEDD8 Antibodyhttp://texas.technologypublisher.com/technology/8055 Anti-NEDD8 Monoclonal Antibody Market: Regulation of the cell cycle involves steps that are critical to cell survival, including the detection and repair of genetic damage as well as the prevention of uncontrolled cell division. Studies on the cell cycle impact huge market sectors such as oncology. Background: Neural precursor cell expressed, developmentally down-regulated 8 (NEDD8) is a ubiquitin-like protein that modulates the cullin subunits of SCF ubiquitin E3 ligases. NEDDylation of the cullins is required for recruitment of E2 to the ligase complex, facilitating ubiquitin conjugat...Wed, 19 Oct 2011 08:26:58 GMTuthsch-otm@uth.tmc.eduhttp://texas.technologypublisher.com/technology/8055Adenosine Deaminase Deficient Transgenic Mice: Testing Ground for Asthma Therapieshttp://texas.technologypublisher.com/technology/8054 Adenosine Deaminase Deficient Transgenic Mice and Methods and Uses Thereof Market: Restrictive lung disease, including asthma, SCID, chronic obstructive pulmonary disease (COPD), and pulmonary fibrosis, is a prevalent condition. In the US asthma affected 29.5 million people in 2005. Asthmatics visited the doctor in offices and outpatient clinics 14.6 million times in 2004, and there were 1.8 million visits to the emergency room. Unfortunately, asthma was the cause of death for 3,780 people in the US in 2004. Likewise, COPD, including emphysema and chronic bronchitis, affect many people...Wed, 19 Oct 2011 08:26:57 GMTuthsch-otm@uth.tmc.eduhttp://texas.technologypublisher.com/technology/8054Thioaptamer oligonucleotide ligands against endothelial E-selectin protein.http://texas.technologypublisher.com/technology/8052Wed, 19 Oct 2011 07:45:34 GMTuthsch-otm@uth.tmc.eduhttp://texas.technologypublisher.com/technology/8052Method to perform Axial-shear strain imaging for tumor classificationhttp://texas.technologypublisher.com/technology/8051Tue, 18 Oct 2011 16:04:55 GMTuthsch-otm@uth.tmc.eduhttp://texas.technologypublisher.com/technology/8051Inhibitors of C-Reactive Protein Induced Vascular Inflammation and Their Usehttp://texas.technologypublisher.com/technology/7770Market: Information collected by the Centers for Disease Control and Prevention during 2006 showed that cardiovascular disease (CVD) from all causes accounts for 29% of deaths worldwide and ranks second only to infectious and parasitic diseases. In the United States alone, atherosclerosis reportedly affects one in four persons, causing approximately 42% of all deaths. With a market size of more than $15 billion, the market for novel atherosclerosis therapies has very lucrative potential. Competitors and Current Problems: Inflammatory response plays an important role in the onset, develo...Mon, 22 Aug 2011 16:19:47 GMTuthsch-otm@uth.tmc.eduhttp://texas.technologypublisher.com/technology/7770Elastography: Highly Sensitive Ultrasound Imaging of Tissue Elasticity In Vivo for Detection and Evaluation of Breast Cancer and Other Elastic Abnormalitieshttp://texas.technologypublisher.com/technology/7733 Market: Market reports indicate that the ultrasound market in Europe was estimated at $719.0 million in 2006, with growth expected to reach $1 billion in 2013. Similarly, the ultrasound market in the United States was estimated at $1.27 billion in 2003. With an estimated 31.2 million patient exams in 2004 conducted by traditional clinical ultrasound segments alone, in addition to the recent adoption of ultrasound imaging by new user groups including surgeons, anesthesiologists, and emergency physicians, the ultrasound market is expected to continue to spur rapid new growth.Current Prob...Mon, 08 Aug 2011 15:34:50 GMTuthsch-otm@uth.tmc.eduhttp://texas.technologypublisher.com/technology/7733Fast Auto-Focus: Must-have technology for next generation digital camerashttp://texas.technologypublisher.com/technology/7635Mon, 18 Jul 2011 12:38:11 GMTbrent.schultze@utdallas.eduhttp://texas.technologypublisher.com/technology/7635Electrolyte-Free Charge Injection Tuning of Carbon Nanotube Sheets – Offering Novel Supercapacitor Technologyhttp://texas.technologypublisher.com/technology/7332Wed, 06 Jul 2011 11:38:17 GMTbrent.schultze@utdallas.eduhttp://texas.technologypublisher.com/technology/7332Smart Auto Exposure for Digital and Cell Phone Cameras and Imaging Systemshttp://texas.technologypublisher.com/technology/7331Wed, 06 Jul 2011 11:08:08 GMTbrent.schultze@utdallas.eduhttp://texas.technologypublisher.com/technology/7331Polymer-Free Carbon Nanotube Assemblieshttp://texas.technologypublisher.com/technology/7330This invention is a novel method for processing nanotube powders into polymer-free structures that have superior electrical, mechanical, and electrochemical properties to those of existing polymer-inclusive structures. Flocculation fiber spinning of carbon nanotubes from aqueous dispersions with the aide of polymer-free flocculating agents produces structures such as fibers, ribbons, ropes, yarns and films of carbon nanotubes. As a result, the properties of fibers are determined by carbon nanotubes only; they are not affected by the presence of a polymeric binder.Overcoming limitations on low ...Wed, 06 Jul 2011 11:03:59 GMTbrent.schultze@utdallas.eduhttp://texas.technologypublisher.com/technology/7330Fuel-Powered Artificial Muscleshttp://texas.technologypublisher.com/technology/7327Wed, 06 Jul 2011 09:39:33 GMTbrent.schultze@utdallas.eduhttp://texas.technologypublisher.com/technology/7327Potent HDAC Inhibitors for the Treatment of Cancers and Sickle Cell Diseasehttp://texas.technologypublisher.com/technology/7325Wed, 06 Jul 2011 07:37:56 GMTbrent.schultze@utdallas.eduhttp://texas.technologypublisher.com/technology/7325Methods and Compositions for the Detection of Functional Clostridium Difficile Toxinshttp://texas.technologypublisher.com/technology/7307Thu, 30 Jun 2011 14:03:10 GMTuthsch-otm@uth.tmc.eduhttp://texas.technologypublisher.com/technology/7307Method and System for Improving SPECT Imaging Resolutionhttp://texas.technologypublisher.com/technology/7304Thu, 30 Jun 2011 11:14:49 GMTbrent.schultze@utdallas.eduhttp://texas.technologypublisher.com/technology/7304Logistical Tracking System: 21st Century Facilities Managementhttp://texas.technologypublisher.com/technology/7301Thu, 30 Jun 2011 11:00:57 GMTbrent.schultze@utdallas.eduhttp://texas.technologypublisher.com/technology/7301User Cooperation Diversity in Signal Coding for Wireless Communicationhttp://texas.technologypublisher.com/technology/7298This invention is a software solution that builds on the concept of user cooperation in wireless communications and displays benefits across virtually all wireless standards and industries. It results in a significant improvement in voice clarity, higher data speeds, and lower transmission power. User coded cooperative wireless communication technology is the latest innovation in which two wireless devices jointly transmit their signals using both of their antennas to diversify the signal that the base station is receiving. By incorporating cooperation with existing error detection and correct...Tue, 28 Jun 2011 14:59:19 GMTbrent.schultze@utdallas.eduhttp://texas.technologypublisher.com/technology/7298Novel and Non-Invasive Imaging of Pancreatic Beta Cellshttp://texas.technologypublisher.com/technology/7264Fri, 10 Jun 2011 09:38:50 GMTbrent.schultze@utdallas.eduhttp://texas.technologypublisher.com/technology/7264Heat Treatment of Inflamed Tissuehttp://texas.technologypublisher.com/technology/6610 Market: Coronary artery disease is a leading cause of death in industrialized countries. It is manifested by atherosclerotic plaques, which are thickened areas in vessel walls made up of an accumulation of cholesterol, proliferating smooth muscle cells and inflammatory cells. In 2004, it was reported that over 1 million Americans underwent an angioplasty procedure to correct the build up of these plaques, contributing partly to interventional cardiology market revenue in excess of $4 billion. Competitors and Current Problems: Many techniques have been developed to identify and remove t...Tue, 22 Mar 2011 08:15:07 GMTuthsch-otm@uth.tmc.eduhttp://texas.technologypublisher.com/technology/6610Device to Prevent Nocturnal Drying of the Oral Cavityhttp://texas.technologypublisher.com/technology/6609Tue, 22 Mar 2011 08:07:39 GMTuthsch-otm@uth.tmc.eduhttp://texas.technologypublisher.com/technology/6609Automated Catheter Insertion Systemhttp://texas.technologypublisher.com/technology/6608 Market: Robotic assisted surgeries are on the rise, up from generally 20,000 robotic assisted procedures in the United States in 2005, to 80,000 robotic assisted prostatectomy procedures alone in 2009. Such robotic assisted surgeries allow for greater precision, smaller incisions and therefore less patient blood loss and quicker patient recovery, but require a highly skilled robotic operator for efficient implementation. Prices of existing surgical systems range from $700,000 to $2.25 million per system, and their presence in hospitals has increased by more than 400% since 2004. Compet...Tue, 22 Mar 2011 08:01:31 GMTuthsch-otm@uth.tmc.eduhttp://texas.technologypublisher.com/technology/6608Collagen-binding Proteins from Enterococcal Bacteriahttp://texas.technologypublisher.com/technology/6413Wed, 02 Feb 2011 13:08:22 GMTuthsch-otm@uth.tmc.eduhttp://texas.technologypublisher.com/technology/6413Apparatus and Method for Palpographic Characterization of Vulnerable Plaque and Other Biological Tissuehttp://texas.technologypublisher.com/technology/6412Wed, 02 Feb 2011 13:08:22 GMTuthsch-otm@uth.tmc.eduhttp://texas.technologypublisher.com/technology/6412A Novel Calpain-Like Cysteine Protease in Type 2 Diabeteshttp://texas.technologypublisher.com/technology/6411 Market: The World Health Organization (WHO) has estimated that the diabetes 2 market will more than double by 2030. In the United States type 2 diabetes affected 20.8 million people in the year 2000. The number of patients diagnosed with diabetes 2 has been continuously increasing. Approximately 90% of all diabetes cases in the United States are of type 2. With a market size of more than $11.2 billion in the US alone, there is a significant and growing market looking for better treatment options. Competitors and Current Problems: Genome-wide screens for susceptibility genes for complex...Wed, 02 Feb 2011 13:08:21 GMTuthsch-otm@uth.tmc.eduhttp://texas.technologypublisher.com/technology/6411Atherosclerosis-Prone Mouse Modelshttp://texas.technologypublisher.com/technology/5881Tue, 19 Oct 2010 07:18:11 GMTuthsch-otm@uth.tmc.eduhttp://texas.technologypublisher.com/technology/5881Alertness Monitoring: A Perceptual Chronometer Device and Method for Measuring Fitness-For-Duty (FFD)http://texas.technologypublisher.com/technology/5880Tue, 19 Oct 2010 07:14:24 GMTuthsch-otm@uth.tmc.eduhttp://texas.technologypublisher.com/technology/5880Filter for Selectively Processing Optical and Other Signalshttp://texas.technologypublisher.com/technology/5532Thu, 05 Aug 2010 15:14:28 GMTbrent.schultze@utdallas.eduhttp://texas.technologypublisher.com/technology/5532System and Method for Configuring Optical Circuitshttp://texas.technologypublisher.com/technology/5529Thu, 05 Aug 2010 15:14:27 GMTbrent.schultze@utdallas.eduhttp://texas.technologypublisher.com/technology/5529Method and Apparatus for Mapping Three-Dimensional Featureshttp://texas.technologypublisher.com/technology/5357Tue, 22 Jun 2010 15:46:15 GMTbrent.schultze@utdallas.eduhttp://texas.technologypublisher.com/technology/5357Generation of Monoclonal Antibodies which specifically recognize osteocytes-specific antigenshttp://texas.technologypublisher.com/technology/5325Fri, 18 Jun 2010 07:43:06 GMTsaenzv@uthscsa.eduhttp://texas.technologypublisher.com/technology/5325A Method of Storage and Controlled Delivery of Nitric Oxidehttp://texas.technologypublisher.com/technology/2760Tue, 16 Jun 2009 12:11:01 GMTbrent.schultze@utdallas.eduhttp://texas.technologypublisher.com/technology/2760A Method of Nitric Oxide Delivery for Healing and Organ Preservationhttp://texas.technologypublisher.com/technology/2302Mon, 18 May 2009 15:16:25 GMTbrent.schultze@utdallas.eduhttp://texas.technologypublisher.com/technology/2302